MA38724A1 - Formulation liquide stable d'amg 416 (velcalcétide) - Google Patents
Formulation liquide stable d'amg 416 (velcalcétide)Info
- Publication number
- MA38724A1 MA38724A1 MA38724A MA38724A MA38724A1 MA 38724 A1 MA38724 A1 MA 38724A1 MA 38724 A MA38724 A MA 38724A MA 38724 A MA38724 A MA 38724A MA 38724 A1 MA38724 A1 MA 38724A1
- Authority
- MA
- Morocco
- Prior art keywords
- velcalctide
- amg
- liquid formulation
- stable liquid
- formulation
- Prior art date
Links
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04D—NON-POSITIVE-DISPLACEMENT PUMPS
- F04D25/00—Pumping installations or systems
- F04D25/02—Units comprising pumps and their driving means
- F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
- F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
- F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
- F01D15/10—Adaptations for driving, or combinations with, electric generators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne une formulation liquide comprenant un agoniste peptidique du récepteur sensible au calcium, et un procédé de préparation et d'utilisation de cette formulation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361840618P | 2013-06-28 | 2013-06-28 | |
PCT/US2014/044622 WO2014210489A1 (fr) | 2013-06-28 | 2014-06-27 | Formulation liquide stable d'amg 416 (velcalcétide) |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38724A1 true MA38724A1 (fr) | 2017-03-31 |
MA38724B1 MA38724B1 (fr) | 2017-11-30 |
Family
ID=51213030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38724A MA38724B1 (fr) | 2013-06-28 | 2014-06-27 | Formulation liquide stable d'amg 416 (velcalcétide) |
Country Status (38)
Country | Link |
---|---|
US (4) | US9820938B2 (fr) |
EP (3) | EP3246017B1 (fr) |
JP (1) | JP6027708B2 (fr) |
KR (1) | KR102231957B1 (fr) |
CN (2) | CN105764487A (fr) |
AP (1) | AP2015008936A0 (fr) |
AR (1) | AR096773A1 (fr) |
AU (1) | AU2014302122B2 (fr) |
CA (1) | CA2916222C (fr) |
CL (1) | CL2015003738A1 (fr) |
CR (2) | CR20160002A (fr) |
CY (1) | CY1120811T1 (fr) |
DK (1) | DK3013318T3 (fr) |
EA (1) | EA030220B1 (fr) |
ES (1) | ES2633989T3 (fr) |
HK (1) | HK1222557A1 (fr) |
HR (1) | HRP20171092T1 (fr) |
HU (1) | HUE034209T2 (fr) |
IL (1) | IL243210B (fr) |
JO (1) | JO3817B1 (fr) |
LT (1) | LT3013318T (fr) |
MA (1) | MA38724B1 (fr) |
ME (1) | ME02818B (fr) |
MX (1) | MX2015017952A (fr) |
MY (1) | MY180276A (fr) |
PE (2) | PE20210413A1 (fr) |
PH (1) | PH12015502816B1 (fr) |
PL (1) | PL3013318T3 (fr) |
PT (1) | PT3013318T (fr) |
RS (1) | RS56238B1 (fr) |
SG (1) | SG11201510647TA (fr) |
SI (1) | SI3013318T1 (fr) |
TN (1) | TN2015000569A1 (fr) |
TW (1) | TWI635874B (fr) |
UA (1) | UA115373C2 (fr) |
UY (1) | UY35636A (fr) |
WO (1) | WO2014210489A1 (fr) |
ZA (1) | ZA201600238B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3246017B1 (fr) | 2013-06-28 | 2021-03-24 | Amgen Inc. | Formulation liquide stable d'amg 416 hcl (etelcalcetide) |
EP4219526A3 (fr) | 2014-04-03 | 2023-08-30 | Amgen, Inc. | Procédé de préparation d'amg-24ib |
US10858389B2 (en) | 2015-03-26 | 2020-12-08 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
CN106137979A (zh) * | 2015-03-31 | 2016-11-23 | 深圳翰宇药业股份有限公司 | 一种冻干粉针剂及其制备方法 |
CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
CN110054662B (zh) * | 2018-01-18 | 2021-03-02 | 成都圣诺生物制药有限公司 | 一种固相合成Etelcalcetide的方法 |
JP2023525884A (ja) | 2020-05-15 | 2023-06-19 | アムジェン インコーポレイテッド | 左室肥大の処置方法 |
CN111925415A (zh) * | 2020-08-10 | 2020-11-13 | 海南中和药业股份有限公司 | 一种维拉卡肽杂质的制备方法 |
WO2022034545A1 (fr) * | 2020-08-14 | 2022-02-17 | Aurobindo Pharma Limited | Formulations d'ételcalcetide à usage parentéral |
EP4333805A1 (fr) | 2021-05-06 | 2024-03-13 | Amgen Inc. | Formulations d'ételcalcétide |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69703121D1 (de) | 1996-10-25 | 2000-10-19 | Us Health | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit |
AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
JP4936884B2 (ja) * | 2003-06-03 | 2012-05-23 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
WO2004105781A2 (fr) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Compositions pharmaceutiques peptidiques stabilisees |
US7265092B2 (en) | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
EP2086321B1 (fr) | 2006-11-16 | 2016-08-31 | Kai Pharmaceuticals, Inc. | Peptides modulateurs du calcium polycationique pour le traitement des troubles de l'hyperparathyroïdie et l'hypercalcémie |
KR102274003B1 (ko) * | 2007-01-19 | 2021-07-08 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
EP2264138B2 (fr) | 2009-06-19 | 2023-03-08 | The Procter & Gamble Company | Composition de détergent liquide pour lavage de la vaisselle à la main |
EP2459208B1 (fr) | 2009-07-29 | 2016-09-28 | Kai Pharmaceuticals, Inc. | Agents thérapeutiques pour réduire les niveaux d' hormone parathyroïdienne |
EP2399604A1 (fr) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Nouvelle formulation d'anticorps |
WO2012075375A1 (fr) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Administration d'hormones parathyroïdiennes par des systèmes de micro-injection |
AU2012267470C1 (en) | 2011-06-08 | 2017-09-21 | Kai Pharmaceuticals, Inc. | Therapeutic agents for regulating serum phosphorus |
CA2854911C (fr) | 2011-11-10 | 2019-09-24 | Kai Pharmaceuticals, Inc. | Calcimimetiques et procedes pour leur utilisation |
EP3246017B1 (fr) | 2013-06-28 | 2021-03-24 | Amgen Inc. | Formulation liquide stable d'amg 416 hcl (etelcalcetide) |
EP4219526A3 (fr) * | 2014-04-03 | 2023-08-30 | Amgen, Inc. | Procédé de préparation d'amg-24ib |
-
2014
- 2014-06-27 EP EP17160312.9A patent/EP3246017B1/fr active Active
- 2014-06-27 SG SG11201510647TA patent/SG11201510647TA/en unknown
- 2014-06-27 PT PT147420939T patent/PT3013318T/pt unknown
- 2014-06-27 MY MYPI2015003044A patent/MY180276A/en unknown
- 2014-06-27 RS RS20170704A patent/RS56238B1/sr unknown
- 2014-06-27 SI SI201430290T patent/SI3013318T1/sl unknown
- 2014-06-27 WO PCT/US2014/044622 patent/WO2014210489A1/fr active Application Filing
- 2014-06-27 KR KR1020167002370A patent/KR102231957B1/ko active IP Right Grant
- 2014-06-27 AU AU2014302122A patent/AU2014302122B2/en active Active
- 2014-06-27 MX MX2015017952A patent/MX2015017952A/es active IP Right Grant
- 2014-06-27 DK DK14742093.9T patent/DK3013318T3/en active
- 2014-06-27 CN CN201480047399.7A patent/CN105764487A/zh active Pending
- 2014-06-27 CA CA2916222A patent/CA2916222C/fr active Active
- 2014-06-27 ME MEP-2017-150A patent/ME02818B/fr unknown
- 2014-06-27 TN TN2015000569A patent/TN2015000569A1/en unknown
- 2014-06-27 JP JP2016524250A patent/JP6027708B2/ja active Active
- 2014-06-27 CR CR20160002A patent/CR20160002A/es unknown
- 2014-06-27 EP EP14742093.9A patent/EP3013318B1/fr active Active
- 2014-06-27 LT LTEP14742093.9T patent/LT3013318T/lt unknown
- 2014-06-27 ES ES14742093.9T patent/ES2633989T3/es active Active
- 2014-06-27 PE PE2020001772A patent/PE20210413A1/es unknown
- 2014-06-27 UA UAA201600641A patent/UA115373C2/uk unknown
- 2014-06-27 MA MA38724A patent/MA38724B1/fr unknown
- 2014-06-27 PE PE2015002666A patent/PE20160549A1/es unknown
- 2014-06-27 PL PL14742093T patent/PL3013318T3/pl unknown
- 2014-06-27 EP EP21156687.2A patent/EP3878433A1/fr active Pending
- 2014-06-27 CN CN202111597304.7A patent/CN114376970A/zh active Pending
- 2014-06-27 US US14/908,481 patent/US9820938B2/en active Active
- 2014-06-27 HU HUE14742093A patent/HUE034209T2/en unknown
- 2014-06-27 TW TW103122433A patent/TWI635874B/zh active
- 2014-06-27 EA EA201690099A patent/EA030220B1/ru not_active IP Right Cessation
- 2014-06-27 CR CR20160061A patent/CR20160061A/es unknown
- 2014-06-27 AP AP2015008936A patent/AP2015008936A0/xx unknown
- 2014-06-29 JO JOP/2014/0204A patent/JO3817B1/ar active
- 2014-06-30 UY UY0001035636A patent/UY35636A/es not_active Application Discontinuation
- 2014-06-30 AR ARP140102450A patent/AR096773A1/es not_active Application Discontinuation
-
2015
- 2015-12-17 IL IL243210A patent/IL243210B/en active IP Right Grant
- 2015-12-17 PH PH12015502816A patent/PH12015502816B1/en unknown
- 2015-12-28 CL CL2015003738A patent/CL2015003738A1/es unknown
-
2016
- 2016-01-12 ZA ZA2016/00238A patent/ZA201600238B/en unknown
- 2016-09-12 HK HK16110762.7A patent/HK1222557A1/zh unknown
-
2017
- 2017-07-17 HR HRP20171092TT patent/HRP20171092T1/hr unknown
- 2017-07-19 CY CY171100771T patent/CY1120811T1/el unknown
- 2017-11-02 US US15/802,390 patent/US10344765B2/en active Active
-
2019
- 2019-06-03 US US16/430,322 patent/US11162500B2/en active Active
-
2021
- 2021-08-11 US US17/400,044 patent/US11959486B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38724A1 (fr) | Formulation liquide stable d'amg 416 (velcalcétide) | |
EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
CL2015002098A1 (es) | “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct | |
CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
CL2016000221A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
EA201891336A1 (ru) | Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
CL2015003290A1 (es) | Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4). | |
CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
AR094403A1 (es) | Terapia de combinación de anticuerpos anti-her3 | |
EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
MX2015016825A (es) | Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculos y sus usos. | |
UY34730A (es) | Formulaciones farmacéuticas que comprenden antagonistas de ccr3 | |
PH12018502274A1 (en) | Semaglutide in cardiovascular conditions | |
EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств | |
EA201491959A1 (ru) | Агонистические пептиды для par4 | |
CL2014001871A1 (es) | Compuestos derivados de espiroindolina sustituidos, antagonistas del receptor de la hormona liberadora de gonadotropina (gnrh); y composicion farmaceutica que los comprende. | |
EA201501123A8 (ru) | Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы | |
BR112016027133A8 (pt) | derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso | |
AR098556A1 (es) | Aparato para procesar información, aparato de difusión y método de recepción | |
SA516370737B1 (ar) | Cgrp صيغ لمضادات مستقبل | |
PH12016500044A1 (en) | Vasopressin-2 receptor agonists | |
MX2017000519A (es) | Derivados de azaspiro(4.5)decano sustituido. | |
UA88242U (ru) | Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия | |
TH166746B (th) | สูตรตำรับของเหลวเสถียร |